Published in Proc Natl Acad Sci U S A on January 19, 2010
Regulation of cancer cell metabolism. Nat Rev Cancer (2011) 15.44
MYC on the path to cancer. Cell (2012) 8.65
Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov (2011) 5.79
Links between metabolism and cancer. Genes Dev (2012) 5.27
Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell (2010) 5.02
How cancer metabolism is tuned for proliferation and vulnerable to disruption. Nature (2012) 3.77
Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis (2013) 3.07
The histone deacetylase SIRT6 is a tumor suppressor that controls cancer metabolism. Cell (2012) 2.78
Evolutionary dynamics of carcinogenesis and why targeted therapy does not work. Nat Rev Cancer (2012) 2.71
Metabolic targets for cancer therapy. Nat Rev Drug Discov (2013) 2.32
Therapeutic targets in cancer cell metabolism and autophagy. Nat Biotechnol (2012) 2.27
Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review. Front Pharmacol (2011) 2.24
The Warburg effect dictates the mechanism of butyrate-mediated histone acetylation and cell proliferation. Mol Cell (2012) 2.20
MYC, metabolism, cell growth, and tumorigenesis. Cold Spring Harb Perspect Med (2013) 2.19
Targeting lactate metabolism for cancer therapeutics. J Clin Invest (2013) 2.14
CD147 subunit of lactate/H+ symporters MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of glycolytic tumors. Proc Natl Acad Sci U S A (2011) 2.06
13C-pyruvate imaging reveals alterations in glycolysis that precede c-Myc-induced tumor formation and regression. Cell Metab (2011) 2.05
Cell-state-specific metabolic dependency in hematopoiesis and leukemogenesis. Cell (2014) 2.01
Disrupting proton dynamics and energy metabolism for cancer therapy. Nat Rev Cancer (2013) 1.93
Targeting lactate dehydrogenase--a inhibits tumorigenesis and tumor progression in mouse models of lung cancer and impacts tumor-initiating cells. Cell Metab (2014) 1.92
KRAS: feeding pancreatic cancer proliferation. Trends Biochem Sci (2014) 1.85
Cancer metabolism: a therapeutic perspective. Nat Rev Clin Oncol (2016) 1.83
Targeting glucose metabolism for cancer therapy. J Exp Med (2012) 1.64
Therapeutic targeting of cancer cell metabolism. J Mol Med (Berl) (2011) 1.62
c-Myc and cancer metabolism. Clin Cancer Res (2012) 1.60
Tumor glycolysis as a target for cancer therapy: progress and prospects. Mol Cancer (2013) 1.57
Combinatorial regulation of neuroblastoma tumor progression by N-Myc and hypoxia inducible factor HIF-1alpha. Cancer Res (2010) 1.57
SAICAR stimulates pyruvate kinase isoform M2 and promotes cancer cell survival in glucose-limited conditions. Science (2012) 1.52
Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism. Cancer Res (2013) 1.49
Empowering self-renewal and differentiation: the role of mitochondria in stem cells. J Mol Med (Berl) (2010) 1.47
Blocking lactate export by inhibiting the Myc target MCT1 Disables glycolysis and glutathione synthesis. Cancer Res (2013) 1.46
Targeting glycogen metabolism in bladder cancer. Nat Rev Urol (2015) 1.46
Tyrosine phosphorylation of lactate dehydrogenase A is important for NADH/NAD(+) redox homeostasis in cancer cells. Mol Cell Biol (2011) 1.42
Cancer cell metabolism: implications for therapeutic targets. Exp Mol Med (2013) 1.39
Hedgehog controls hepatic stellate cell fate by regulating metabolism. Gastroenterology (2012) 1.36
Pyruvate kinase M2 regulates glucose metabolism by functioning as a coactivator for hypoxia-inducible factor 1 in cancer cells. Oncotarget (2011) 1.33
Mouse genetics suggests cell-context dependency for Myc-regulated metabolic enzymes during tumorigenesis. PLoS Genet (2012) 1.31
MYC, Metabolism, and Cancer. Cancer Discov (2015) 1.29
Stable isotope-resolved metabolomics and applications for drug development. Pharmacol Ther (2011) 1.29
Lysine-5 acetylation negatively regulates lactate dehydrogenase A and is decreased in pancreatic cancer. Cancer Cell (2013) 1.29
Cancer metabolic reprogramming: importance, main features, and potentials for precise targeted anti-cancer therapies. Cancer Biol Med (2014) 1.27
Design, synthesis, and pharmacological evaluation of bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide 3 (BPTES) analogs as glutaminase inhibitors. J Med Chem (2012) 1.27
Stalling the engine of resistance: targeting cancer metabolism to overcome therapeutic resistance. Cancer Res (2013) 1.19
Alterations of metabolic genes and metabolites in cancer. Semin Cell Dev Biol (2012) 1.18
Anticancer agents that counteract tumor glycolysis. ChemMedChem (2012) 1.17
Inhibition of glycolytic enzymes mediated by pharmacologically activated p53: targeting Warburg effect to fight cancer. J Biol Chem (2011) 1.16
PDK1 inhibition is a novel therapeutic target in multiple myeloma. Br J Cancer (2012) 1.16
Oncology's energetic pipeline. Nat Biotechnol (2010) 1.14
Genome-wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic target. J Pathol (2012) 1.14
Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev (2016) 1.13
Lactate dehydrogenase B: a metabolic marker of response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res (2013) 1.12
Targeting the metabolic microenvironment of tumors. Adv Pharmacol (2012) 1.11
The Warburg effect in tumor progression: mitochondrial oxidative metabolism as an anti-metastasis mechanism. Cancer Lett (2014) 1.11
Metabolism and brain cancer. Clinics (Sao Paulo) (2011) 1.10
Targeting glucose metabolism in patients with cancer. Cancer (2013) 1.10
Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data. Haematologica (2012) 1.09
Fundamentals of cancer metabolism. Sci Adv (2016) 1.09
MYC and metabolism on the path to cancer. Semin Cell Dev Biol (2015) 1.09
Targeting aerobic glycolysis: 3-bromopyruvate as a promising anticancer drug. J Bioenerg Biomembr (2012) 1.08
Isotopically nonstationary 13C flux analysis of Myc-induced metabolic reprogramming in B-cells. Metab Eng (2012) 1.08
The Warburg effect: evolving interpretations of an established concept. Free Radic Biol Med (2014) 1.07
MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism. Proc Natl Acad Sci U S A (2015) 1.07
SoNar, a Highly Responsive NAD+/NADH Sensor, Allows High-Throughput Metabolic Screening of Anti-tumor Agents. Cell Metab (2015) 1.06
Lactate dehydrogenase A is a potential prognostic marker in clear cell renal cell carcinoma. Mol Cancer (2014) 1.05
FOXM1 promotes the warburg effect and pancreatic cancer progression via transactivation of LDHA expression. Clin Cancer Res (2014) 1.05
Quinoline 3-sulfonamides inhibit lactate dehydrogenase A and reverse aerobic glycolysis in cancer cells. Cancer Metab (2013) 1.04
Molecular Pathways: Targeting MYC-induced metabolic reprogramming and oncogenic stress in cancer. Clin Cancer Res (2013) 1.04
Lactate dehydrogenase A silencing in IDH mutant gliomas. Neuro Oncol (2013) 1.04
Dysregulated metabolism contributes to oncogenesis. Semin Cancer Biol (2015) 1.03
Metabolic imaging: a link between lactate dehydrogenase A, lactate, and tumor phenotype. Clin Cancer Res (2011) 1.03
Mitochondrial and plasma membrane lactate transporter and lactate dehydrogenase isoform expression in breast cancer cell lines. Physiol Genomics (2010) 1.03
Functional interactions among members of the MAX and MLX transcriptional network during oncogenesis. Biochim Biophys Acta (2014) 1.02
Conceptual framework for cutting the pancreatic cancer fuel supply. Clin Cancer Res (2012) 1.02
Metabolism addiction in pancreatic cancer. Cell Death Dis (2014) 1.02
Emerging metabolic targets in cancer therapy. Front Biosci (Landmark Ed) (2011) 1.02
Paracrine Hedgehog signaling drives metabolic changes in hepatocellular carcinoma. Cancer Res (2012) 1.01
Combination of sulindac and dichloroacetate kills cancer cells via oxidative damage. PLoS One (2012) 1.01
Nicotinamide phosphoribosyl transferase (Nampt) is required for de novo lipogenesis in tumor cells. PLoS One (2012) 1.00
Estrogen-related receptor alpha modulates lactate dehydrogenase activity in thyroid tumors. PLoS One (2013) 1.00
Targeting of NAD metabolism in pancreatic cancer cells: potential novel therapy for pancreatic tumors. Clin Cancer Res (2013) 1.00
Xenohormetic and anti-aging activity of secoiridoid polyphenols present in extra virgin olive oil: a new family of gerosuppressant agents. Cell Cycle (2013) 1.00
Altered energy metabolism in cancer: a unique opportunity for therapeutic intervention. Cancer Biol Ther (2012) 1.00
Quantitative determinants of aerobic glycolysis identify flux through the enzyme GAPDH as a limiting step. Elife (2014) 0.99
The HIF-pathway inhibitor NSC-134754 induces metabolic changes and anti-tumour activity while maintaining vascular function. Br J Cancer (2012) 0.98
Inhibition of LDHA suppresses tumor progression in prostate cancer. Tumour Biol (2015) 0.97
Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia. Br J Cancer (2013) 0.96
Chromosomal instability, tolerance of mitotic errors and multidrug resistance are promoted by tetraploidization in human cells. Cell Cycle (2015) 0.96
Identification of LDH-A as a therapeutic target for cancer cell killing via (i) p53/NAD(H)-dependent and (ii) p53-independent pathways. Oncogenesis (2014) 0.95
Amyloid beta resistance in nerve cell lines is mediated by the Warburg effect. PLoS One (2011) 0.94
Ketogenic diets as an adjuvant cancer therapy: History and potential mechanism. Redox Biol (2014) 0.94
ROS homeostasis and metabolism: a dangerous liason in cancer cells. Cell Death Dis (2016) 0.94
Targeting metabolism to induce cell death in cancer cells and cancer stem cells. Int J Cell Biol (2013) 0.94
Understanding the Intersections between Metabolism and Cancer Biology. Cell (2017) 0.94
Therapeutic Targeting of the Warburg Effect in Pancreatic Cancer Relies on an Absence of p53 Function. Cancer Res (2015) 0.93
Redox control of glutamine utilization in cancer. Cell Death Dis (2014) 0.93
Identification of novel molecular targets for endometrial cancer using a drill-down LC-MS/MS approach with iTRAQ. PLoS One (2011) 0.93
Association of cancer metabolism-related proteins with oral carcinogenesis - indications for chemoprevention and metabolic sensitizing of oral squamous cell carcinoma? J Transl Med (2014) 0.92
Dual targeting of the Warburg effect with a glucose-conjugated lactate dehydrogenase inhibitor. Chembiochem (2013) 0.91
Genome-wide association study identifies two novel regions at 11p15.5-p13 and 1p31 with major impact on acute-phase serum amyloid A. PLoS Genet (2010) 0.91
Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science (2009) 49.82
On the origin of cancer cells. Science (1956) 49.55
Targeting HIF-1 for cancer therapy. Nat Rev Cancer (2003) 28.01
Why do cancers have high aerobic glycolysis? Nat Rev Cancer (2004) 20.60
c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature (2009) 13.28
Cancer cell metabolism: Warburg and beyond. Cell (2008) 11.80
Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell (2008) 11.18
Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell (2006) 9.80
Brick by brick: metabolism and tumor cell growth. Curr Opin Genet Dev (2008) 7.87
Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest (2008) 7.52
Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J Biol Chem (1996) 7.37
HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell (2007) 6.06
c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc Natl Acad Sci U S A (1997) 5.43
Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res (2007) 5.12
HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Cell (2007) 4.81
Oncogenic alterations of metabolism. Trends Biochem Sci (1999) 4.51
FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res (2003) 4.04
Hypoxic regulation of lactate dehydrogenase A. Interaction between hypoxia-inducible factor 1 and cAMP response elements. J Biol Chem (1995) 2.80
Aerobic glycolysis by proliferating cells: a protective strategy against reactive oxygen species. FASEB J (1997) 2.65
LACTIC DEHYDROGENASE IN HUMAN NEOPLASTIC TISSUES. Cancer Res (1964) 2.50
LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer. Mol Cancer Ther (2009) 2.43
Energy deregulation: licensing tumors to grow. Science (2006) 2.31
The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies. Blood (2009) 2.28
Mitochondria in cancer: not just innocent bystanders. Semin Cancer Biol (2008) 2.23
Evaluation of myc E-box phylogenetic footprints in glycolytic genes by chromatin immunoprecipitation assays. Mol Cell Biol (2004) 2.19
Identification of putative c-Myc-responsive genes: characterization of rcl, a novel growth-related gene. Mol Cell Biol (1997) 1.92
Glycolysis, respiration, and anomalous gene expression in experimental hepatomas: G.H.A. Clowes memorial lecture. Cancer Res (1972) 1.54
The Warburg effect suppresses oxidative stress induced apoptosis in a yeast model for cancer. PLoS One (2009) 1.31
Lactate dehydrogenase M-subunit deficiency: a new type of hereditary exertional myopathy. Clin Chim Acta (1988) 1.30
Selective active site inhibitors of human lactate dehydrogenases A4, B4, and C4. Biochem Pharmacol (2001) 1.30
Selective inhibitors of human lactate dehydrogenases and lactate dehydrogenase from the malarial parasite Plasmodium falciparum. J Med Chem (1998) 1.26
Effect of extracellular AMP on cell proliferation and metabolism of breast cancer cell lines with high and low glycolytic rates. J Biol Chem (1997) 1.14
Lactate dehydrogenase 5 expression in non-Hodgkin B-cell lymphomas is associated with hypoxia regulated proteins. Leuk Lymphoma (2008) 0.98
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02
c-Myc-regulated microRNAs modulate E2F1 expression. Nature (2005) 31.81
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell (2003) 15.43
Development of human protein reference database as an initial platform for approaching systems biology in humans. Genome Res (2003) 14.79
Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell (2007) 14.58
c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature (2009) 13.28
HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab (2006) 13.22
Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell (2007) 13.04
Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet (2007) 10.78
DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science (2011) 10.26
Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer (2011) 9.68
EMT and dissemination precede pancreatic tumor formation. Cell (2012) 9.27
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature (2012) 8.31
Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature (2003) 8.14
Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia. J Biol Chem (2008) 7.71
Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science (2009) 7.39
Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell (2011) 7.33
Cancer's molecular sweet tooth and the Warburg effect. Cancer Res (2006) 7.24
Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature (2004) 6.82
HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells. Cell (2007) 6.31
Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol (2011) 6.16
HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell (2007) 6.06
Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood (2004) 5.71
Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. Cell (2011) 5.63
An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res (2006) 5.52
Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell (2003) 5.36
Global mapping of c-Myc binding sites and target gene networks in human B cells. Proc Natl Acad Sci U S A (2006) 5.27
Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res (2007) 5.12
Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med (2011) 5.03
Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell (2010) 5.02
Myc stimulates nuclearly encoded mitochondrial genes and mitochondrial biogenesis. Mol Cell Biol (2005) 4.99
Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations. Cancer Res (2006) 4.83
HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Cell (2007) 4.81
Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab (2012) 4.80
Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proc Natl Acad Sci U S A (2008) 4.79
An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol (2004) 4.74
Expression of Yes-associated protein in common solid tumors. Hum Pathol (2008) 4.61
Altered telomeres in tumors with ATRX and DAXX mutations. Science (2011) 4.60
An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets. Genome Biol (2003) 4.49
Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders. Blood (2009) 4.22
Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat Genet (2002) 4.06
Candidate exome capture identifies mutation of SDCCAG8 as the cause of a retinal-renal ciliopathy. Nat Genet (2010) 3.99
Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol (2006) 3.98
Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation. Proc Natl Acad Sci U S A (2009) 3.76
Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. Hum Mutat (2011) 3.63
Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci U S A (2011) 3.51
Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1. Mol Cell Biol (2007) 3.51
Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer (2003) 3.47
Spontaneous induction of murine pancreatic intraepithelial neoplasia (mPanIN) by acinar cell targeting of oncogenic Kras in adult mice. Proc Natl Acad Sci U S A (2008) 3.43
Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am J Pathol (2003) 3.40
Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. Circ Res (2003) 3.34
Complete loss of ischaemic preconditioning-induced cardioprotection in mice with partial deficiency of HIF-1 alpha. Cardiovasc Res (2007) 3.31
Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res (2010) 3.30
Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res (2003) 3.23
Heterozygous HIF-1alpha deficiency impairs carotid body-mediated systemic responses and reactive oxygen species generation in mice exposed to intermittent hypoxia. J Physiol (2006) 3.12
RACK1 competes with HSP90 for binding to HIF-1alpha and is required for O(2)-independent and HSP90 inhibitor-induced degradation of HIF-1alpha. Mol Cell (2007) 3.09
Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J Natl Cancer Inst (2010) 3.08
Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene (2005) 3.05
Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B. Cancer Res (2006) 3.05
Metabolic regulation of hematopoietic stem cells in the hypoxic niche. Cell Stem Cell (2011) 3.05
The Hippo signaling pathway restricts the oncogenic potential of an intestinal regeneration program. Genes Dev (2010) 3.02
Multifaceted roles of glycolytic enzymes. Trends Biochem Sci (2005) 3.01
Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer. Am J Surg Pathol (2006) 3.01
Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. J Biol Chem (2002) 2.95
Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): a novel strategy for human cancer therapy. J Nanobiotechnology (2007) 2.93
Human embryonic stem cells have a unique epigenetic signature. Genome Res (2006) 2.89
Hypoxia inducible factor 1 mediates hypoxia-induced TRPC expression and elevated intracellular Ca2+ in pulmonary arterial smooth muscle cells. Circ Res (2006) 2.82
Regulation of angiogenesis by hypoxia-inducible factor 1. Crit Rev Oncol Hematol (2006) 2.80
Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. Gastroenterology (2012) 2.74
Hedgehog signaling is required for effective regeneration of exocrine pancreas. Gastroenterology (2008) 2.71
Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury. Circulation (2003) 2.68
Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res (2003) 2.66
Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach. Mol Cell Proteomics (2005) 2.66
Gene expression profiles in pancreatic intraepithelial neoplasia reflect the effects of Hedgehog signaling on pancreatic ductal epithelial cells. Cancer Res (2005) 2.64
A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development. Mol Cancer Ther (2009) 2.61
Pancreatic carcinogenesis. Pancreatology (2008) 2.60
Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol (2002) 2.56
Tumor-initiating cells are rare in many human tumors. Cell Stem Cell (2010) 2.54
HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene (2005) 2.53
Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res (2003) 2.49
SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. Clin Cancer Res (2009) 2.44
Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia. Am J Pathol (2002) 2.44
Effects of aging and hypoxia-inducible factor-1 activity on angiogenic cell mobilization and recovery of perfusion after limb ischemia. Circ Res (2007) 2.43
PTEN activity is modulated during ischemia and reperfusion: involvement in the induction and decay of preconditioning. Circ Res (2005) 2.43
Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol (2011) 2.41
Hypoxia-inducible factor-1 deficiency results in dysregulated erythropoiesis signaling and iron homeostasis in mouse development. J Biol Chem (2006) 2.39
Repression of the miR-143/145 cluster by oncogenic Ras initiates a tumor-promoting feed-forward pathway. Genes Dev (2010) 2.37
Array-based comparative genomic hybridization identifies localized DNA amplifications and homozygous deletions in pancreatic cancer. Neoplasia (2005) 2.35
Defective carotid body function and impaired ventilatory responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1 alpha. Proc Natl Acad Sci U S A (2002) 2.35
Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization. Proc Natl Acad Sci U S A (2009) 2.33